Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

ClinicalTrials.gov ID: NCT03044249

Public ClinicalTrials.gov record NCT03044249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression

Study identification

NCT ID
NCT03044249
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mediti Pharma Inc.
Other
Enrollment
81 participants

Conditions and interventions

Interventions

  • MP-101 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 3, 2017
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020
Last update posted
Mar 31, 2021

2017 – 2020

United States locations

U.S. sites
17
U.S. states
9
U.S. cities
17
Facility City State ZIP Site status
Dignity Health (St. Joseph Hospital and Medical Center) Phoenix Arizona 85013
Neuro-Therapeutics Inc Pasadena California 91105
Associated Neurologists of Southern CT Fairfield Connecticut 06824
Marcus Neuroscience Institute Boca Raton Florida 33486
Meridien Research Brooksville Florida 34601
Galiz Research Hialeah Florida 33016
Galiz Research Miami Springs Florida 33166
CNS Orlando Florida 32801
Parkinson's Disease Treatment Center of SW Florida Port Charlotte Florida 33980
Meridien Research Inc St. Petersburg Florida 33709
University of South Florida Tampa Florida 33613
College Park Family Care Neuro Overland Park Kansas 66212
J. Gary Booker, MD, Clinical Trials Shreveport Louisiana 71104
Alzheimer's Research Corporation Paterson New Jersey 08759
Clarity Clinical Research East Syracuse New York 13057
Richmond Behavioral Associates Staten Island New York 10312
Neurology Diagnostics Inc Dayton Ohio 45459

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03044249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2021 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03044249 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →